# Seaport Therapeutics, Inc. (SPTX)

> Source: Nexqual · https://nexqual.com/SPTX · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Seaport Therapeutics, Inc. (SPTX), nexqual.com/SPTX" · informational, not investment advice.

**Price:** USD 21.1 (+3.53% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 20.38 · day 20.48–22.09 · 52w 14.85–28.38 · market cap $1.13B · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 37 (range 28–50).
- Total return with dividends: 1Y +2.7% vs S&P 500 +14.8%; 5Y +6.3% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.56, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: SPTX paid no cash dividend in the last five years.
- Short interest: 7.30% of float (as of 2026-10-15), 12.2 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 2.7x · FCF yield -7.27% · Earnings yield -10.29%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 37 (low 28, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Canaccord Genuity | Initiated | Buy | $28 |
| 2026-10-08 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-09-25 | Raymond James | Initiated | Strong Buy | $46 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-08-26 | Jones Trading | Initiated | Buy | $32 |
| 2026-08-20 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-08-04 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-07-15 | HC Wainwright & Co. | Initiated | Buy | $50 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-05-01) | 5Y (from 2026-04-27) |
|---|---|---|
| Total return | +2.7% | +6.3% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | — | — |
| Volatility (annualized) | 75.0% | 60.5% |
| Max drawdown | -42.2% (Aug 2026→Oct 2026) | -28.3% (Aug 2026→Oct 2026) |

## Dividends
SPTX paid no cash dividend in the last five years.

## Short interest
3,718,915 shares sold short, 7.30% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 3,148,881 shares (+18.1%). Days to cover: 12.2 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/SPTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.56 | $-0.57 | +$0.01 | $0 | 7 |
| Next quarter (ends 2026-12-31) | $-0.60 | $-0.60 | $0.00 | $0 | 7 |
| Current fiscal year (ends 2026-12-31) | $-5.59 | $-5.11 | −$0.48 | $0 | 7 |
| Next fiscal year (ends 2027-12-31) | $-2.52 | $-2.47 | −$0.05 | $0 | 7 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.78 | −$0.66 | Miss −169.7% | — |
| — | Quarter ended Mar 31, 2026 | −$10.34 | −$3.88 | Miss −166.5% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).